Dear editor,
We are happy to clarify several issues Kofke and Sharma raise on SIESTA.
Despite great input from anesthesiologists in most antecedent studies, both ''conscious sedation'' (CS) and general anesthesia (GA) were hardly defined. Official definitions of GA state a ''drug-induced lack of consciousness [. . .] often requir[ing] assistance in maintaining a patent airway . . . .'' 1 The SIESTA-protocol repeatedly confirms GA to involve intubation. We have deliberately aimed to avoid differential qualitative effects of drugs by using ''the same'' 2 (p. 971) drugs for analgesia/sedation in both CS and GA, just in different doses, by that indeed acknowledging the principle of ''continuum of depth of sedation.'' 1 While sedation depth is monitored by the Richmond Agitation Sedation Scale, bispectral index and endtidal CO2, these are neither randomization categories, nor the only triggers for conversion to GA, but will be evaluated for utility in subsequent analyses.
SIESTA is not about drugs. It would certainly be wonderful to clarify all effects of different sedatives and co-morbidities in one trial. We just did not know how. So, we addressed all these parameters as secondary outcomes 2 (p. 974) to learn for future trials, but for now decided to alter one periinterventional aspect only and randomize to eliminate confounders.
In contrast to Kofke and Sharma, we are very confident to end up with a conclusive-since prospective-study.
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